NVDA
NVIDIA
-- 115.430 TSLA
Tesla
-- 225.310 INTC
Intel
-- 25.920 GOOG
Alphabet-C
-- 162.670 GOOGL
Alphabet-A
-- 160.670 
NEWS
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
NanoViricides (NYSE:NNVC) announces a corporate presentation at the Spartan Capital Investors Conference 2024 on November 4, featuring their lead drug candidate NV-387. The presentation will highlight NV-387's completion of Phase I clinical trials and its demonstrated antiviral activity against multiple viruses including Influenza, RSV, COVID, and MPox/Smallpox. The company notes that NV-387 targets a market estimated at $2.5 to $4.3 billion for RSV alone, with the overall market for targeted indications projected to exceed $10 billion by 2027.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment